TOSHIBA
23.2.2024 17:44:33 CET | Business Wire | Press release
At EuroCIS 2024, Toshiba Global Commerce Solutions showcases how retailers can “Create Beyond what’s Possible” to transform retail operations and customer experiences with its innovative solutions portfolio (booth in hall 9 #B42). The international trade fair will take place on February 27-29 in Düsseldorf, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240223284358/en/
At EuroCIS 2024, Toshiba Global Commerce Solutions will empower retailers to transform their operations and customer experiences with innovative solutions and services. (Photo: Business Wire)
“Our unified commerce and self-service solutions help retailers create shopping experiences that go beyond consumer expectations,” says Meike Marquardt, Head of Marketing for Europe, Toshiba Global Commerce Solutions. “With Toshiba Global Commerce Solutions as a trusted partner, retailers have the power to adapt effortlessly to the rapidly changing business needs of the industry and to think beyond their limitations.”
During EuroCIS, retailers can experience how Toshiba’s end-to-end solutions backed with the latest innovative technologies empower retailers to transform business with enhanced store insights, operations, and customer experiences. Guests at Toshiba’s booth will encounter self-service solutions that leverage A.I., computer vision, and edge computing technologies that reduce friction and address critical industry challenges like shrink. Toshiba will also feature the Retail Command Center showcasing Connected Services with A.I.-powered analytics that take the store support services model from reactive to proactive. Featured mobile and unified commerce solutions will demonstrate how retailers can evolve with their customers across multiple touchpoints. Solutions in Toshiba’s booth are all part of a composable and modular portfolio that allows retailers to take control of their transformation journey and accelerate change in the way that best suits their business needs.
Self-Service solutions leverage A.I., computer vision and edge computing
- Toshiba’s Vision Kiosk bypasses barcodes completely by automatically identifying and validating items, typically in convenience, pharmacy and specialty stores. The computer vision self-service kiosk offers the ability to buy items quickly and easily using contactless and biometric payments, powered by PopID.
- The TCx® SMART Self Checkout offers multiple customisation options including wall-mounted and freestanding solutions, designed to meet changing self-service expectations across retail segments including grocery, specialty and convenience.
- Toshiba’s Self Checkout System 7 integrates edge computing cameras to minimize shrink while providing consumers enhanced checkout experiences and reduced friction. For produce recognition the TCx EDGEcam leverages A.I. and computer vision integrated with Intel technology to identify produce accurately and fast. Based on retailer data, Toshiba has found that shoppers save as much as five seconds per produce item lookup during checkout. Furthermore, the TCx EDGEcam+ utilizes Qualcomm® System-on-Chip (SoC) technology to enhance loss prevention capabilities, ensuring comprehensive security measures.
A.I.-enabled Connected Services powers operational efficiency in stores
Toshiba’s recently opened Command Center in Brussels is ready to deliver A.I.-enabled Connected Services for retailers. At EuroCIS, retailers will experience the Retail Command Center in real life, showing how A.I.-enabled analytics can identify failure patterns of hardware components and software processes, enabling retailers to drive technology management decisions instantly, changing the store support model from reactive to proactive, minimizing downtime, and lost revenues.
Unified Commerce brings agility to mobile and in-store touchpoints
Modern consumer shopping journeys are constantly evolving, moving from digital to physical, mobile to in-store, and vice-versa. Mobile solutions are a given for shoppers and are essential for in-store staff. Toshiba’s unified commerce makes this easy, leveraging a unified single basket architecture across multiple touchpoints.
Composable and modular software solutions enable retailers to accelerate change
Retailers looking to transform their business and to adopt innovative technologies to meet their consumer expectations can consider solutions to replace a complete platform, as well as composable technologies when wanting to introduce innovative applications step by step. Everything is available in a software-as-a-service (SaaS) model to ease affordability and speed of deployment.
Toshiba will speak on both the Connected Retail & Retail Technology Stages
Toshiba experts will also share their knowledge and expertise on the EuroCIS stages:
February 27 at 12:40 - 1:00 pm on the Connected Retail Stage
How Remote Monitoring can help the retailer to be ahead of the game
Jules Harms, Director Professional Services, Toshiba Global Commerce Solutions
February 28 at 3:00 - 3:20 pm on the Retail Technology Stage
Ground to Cloud – Driving Transformation in Retail
Mike Mooney, Vice President of Solutions, Toshiba Global Commerce Solutions
About Toshiba Global Commerce Solutions:
Toshiba Global Commerce Solutions empowers retail to thrive and prosper through a dynamic ecosystem of smarter, more agile solutions and services that enable retailers to resiliently evolve with generations of consumers and adapt to market conditions. Supported by a global organization of devoted employees and partners, retailers gain more visibility and control over operations while enjoying the flexibility to build, scale, and transform retail experiences that anticipate and fulfill consumers’ ever-changing needs. Visit commerce.toshiba.com and engage with us on X, formerly known as Twitter, Facebook, LinkedIn, Instagram, and YouTube, to learn more.
Toshiba Global Commerce Solutions is a wholly owned subsidiary of Toshiba Tec Corporation, which is traded on the Tokyo Stock Exchange.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240223284358/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
